

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Pro Medicus Limited</b>
<b>ABN</b>	<b>25 006 194 752</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Peter Terence KEMPEN
<b>Date of last notice</b>	21 February 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ordinary fully paid shares in Pro Medicus Limited held by Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member
<b>Date of change</b>	7 March 2023 8 March 2023 9 March 2023 10 March 2023 13 March 2023
<b>No. of securities held prior to change</b>	679,082 ordinary shares consisting of: - <ul style="list-style-type: none"><li>• 200,000 ordinary shares held under Peter Terence KEMPEN</li><li>• 478,082 ordinary shares held under Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member</li><li>• 1,000 ordinary shares held under EMK Investments Pty Ltd of which the Director is a Director and beneficial owner</li></ul>
<b>Class</b>	Ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	Nil
<b>Number disposed</b>	7 March 2023 – 10,000 8 March 2023 – 15,000 9 March 2023 – 11,389 10 March 2023 – 10,000 13 March 2023 – 3,611 <b>Total – 50,000</b>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	7 March 2023 - \$61.5691 per share 8 March 2023 - \$62.1807 per share 9 March 2023 - \$62.7975 per share 10 March 202 - \$61.1922 per share 13 March 2023 - \$61.2443 per share
<b>No. of securities held after change</b>	629,082 ordinary shares consisting of: - <ul style="list-style-type: none"> <li>• 200,000 ordinary shares held under Peter Terence KEMPEN</li> <li>• 428,082 ordinary shares held under Elaine Kempen Superannuation Fund of which the Director is a Trustee and Member</li> <li>• 1,000 ordinary shares held under EMK Investments Pty Ltd of which the Director is a Director and beneficial owner</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market sales of shares

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

For and on behalf of Pro Medicus Limited



Clayton Hatch  
Company Secretary  
14 March 2023

---

<sup>+</sup> See chapter 19 for defined terms.